Artificial intelligence in drug development has transformative potential when it comes to pharma research and development (R&D). Download the white paper to advance the adoption of AI within your organization.
Frost & Sullivan 2022 Competitive Strategy Leader Award North American Artificial Intelligence Enabled Preclinical Development Industry
This study covers one of the many applications of BIOiSIM. Our aim was to establish what the pharmacokinetic (PK) profile would look like in the different subjects studied.
This white paper showcases how fusing artificial intelligence and mechanistic modeling can be used to accurately predict the disposition of small molecules across different subjects for translation to clinical success.
This study covers the development and validation of a transdermal model using the BIOiSIM framework, which was further used to describe the relationship between compound exposure and therapeutic effect.
This study covers one of the many applications of BIOiSIM, simulation of drug disposition after IV administration. Our aim was to train the model on in vivo rat compound data and enable it to perform pharmacokinetic (PK) predictions for IV-administered…